Top Medical Stocks To Research – July 29th

UnitedHealth Group, Novo Nordisk A/S, Eli Lilly and Company, Merck & Co., Inc., Hims & Hers Health, Sarepta Therapeutics, and AstraZeneca are the seven Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares of publicly traded companies operating in the healthcare sector, including pharmaceutical developers, biotechnology firms, medical device manufacturers and healthcare service providers. These equities give investors exposure to innovations in drug discovery, diagnostic tools and treatment technologies. Their performance is often driven by clinical trial results, regulatory approvals, patent expirations and changes in healthcare policy. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

Shares of UNH stock traded down $14.17 on Tuesday, reaching $267.95. 28,643,286 shares of the stock were exchanged, compared to its average volume of 11,509,771. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.85 and a quick ratio of 0.85. UnitedHealth Group has a one year low of $248.88 and a one year high of $630.73. The stock has a 50 day moving average price of $300.91 and a 200 day moving average price of $422.56. The stock has a market cap of $243.07 billion, a PE ratio of 11.21, a P/E/G ratio of 1.39 and a beta of 0.45.

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

NYSE:NVO traded down $14.69 on Tuesday, reaching $54.31. The company’s stock had a trading volume of 86,742,358 shares, compared to its average volume of 9,712,979. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The firm has a market cap of $242.48 billion, a PE ratio of 16.06, a PEG ratio of 1.38 and a beta of 0.64. The business’s 50-day moving average price is $70.71 and its two-hundred day moving average price is $73.51. Novo Nordisk A/S has a 1-year low of $53.51 and a 1-year high of $139.74.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

NYSE LLY traded down $38.85 during trading hours on Tuesday, hitting $769.26. 4,173,533 shares of the company traded hands, compared to its average volume of 3,762,271. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The stock has a market capitalization of $729.06 billion, a price-to-earnings ratio of 62.66, a P/E/G ratio of 1.18 and a beta of 0.40. The business’s 50-day moving average is $773.01 and its 200-day moving average is $800.67. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Shares of NYSE MRK traded down $2.79 during trading hours on Tuesday, reaching $81.27. 18,440,659 shares of the stock were exchanged, compared to its average volume of 15,837,773. The firm has a market capitalization of $204.07 billion, a price-to-earnings ratio of 11.84, a P/E/G ratio of 0.87 and a beta of 0.39. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.16 and a current ratio of 1.41. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $123.94. The stock’s fifty day simple moving average is $80.17 and its 200 day simple moving average is $84.99.

Hims & Hers Health (HIMS)

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health stock traded up $0.91 during mid-day trading on Tuesday, reaching $59.59. 20,711,054 shares of the company were exchanged, compared to its average volume of 33,602,555. The company has a fifty day simple moving average of $53.08 and a 200-day simple moving average of $43.24. Hims & Hers Health has a 12 month low of $13.47 and a 12 month high of $72.98. The firm has a market cap of $13.34 billion, a PE ratio of 86.53, a PEG ratio of 2.13 and a beta of 2.02.

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Shares of SRPT traded up $2.51 during midday trading on Tuesday, hitting $16.37. The company’s stock had a trading volume of 52,095,305 shares, compared to its average volume of 5,330,634. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $146.38. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -6.09 and a beta of 0.45. The company’s fifty day simple moving average is $25.64 and its two-hundred day simple moving average is $62.85.

AstraZeneca (AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

AZN traded up $2.18 during midday trading on Tuesday, hitting $74.01. 10,271,607 shares of the company were exchanged, compared to its average volume of 5,306,008. The firm has a market capitalization of $229.54 billion, a P/E ratio of 29.72, a P/E/G ratio of 1.34 and a beta of 0.37. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. The firm’s 50 day moving average price is $71.20 and its 200-day moving average price is $71.20. AstraZeneca has a 1-year low of $61.24 and a 1-year high of $87.68.